Clinical Trials
Genentech announced the result of Phase II clinical trail of RG7204
Genentech, Inc., a member of the Roche Group announced results from a Phase II clinical study of RG7204 (PLX4032), an investigational first-in-class molecule designed to...
Clinical Trials
Sanofi Pasteur’s Dengue Vaccine in Final Stage of Clinical Development
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that its dengue vaccine is in final stage of clinical development. Sanofi Pasteur’s dengue vaccine, the...
Clinical Trials
Roche reports promising Phase II results with new targeted approach in advanced melanoma
Roche announced results from a Phase II clinical study of RG7204 PLX4032), an investigational first-in-class molecule designed to selectively inhibit a cancer-causing, mutated form of...
Clinical Trials
Genzyme Announces Results of Phase 3 Trial of Clolar in Adult AML
Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine...
Clinical Trials
Boehringer Ingelheim announced approval for TWYNSTA®. TWYNSTA single pill combination that delivers powerful and consistent blood pressure reductions
Boehringer Ingelheim announced today that the European Commission confirmed the positive opinion of the European Medicines Agency (EMA) approving TWYNSTA®. TWYNSTA® is indicated for the...
Clinical Trials
Amgen announced that results from the PRIME ‘203’ and ‘181’ pivotal Phase 3 trials
Amgen announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix(R) (panitumumab) in combination with chemotherapy (FOLFOX or FOLFIRI) as...
Clinical Trials
Bristol-Myers Squibb announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes
Bristol-Myers Squibb Company and AstraZeneca announced results from a randomized, double-blind Phase 3 clinical study in adults with type 2 diabetes inadequately controlled on metformin...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.